The spark? Before the opening bell, Regeneron announced that its scientists had isolated hundreds of virus-neutralizing, fully human antibodies from genetically modified mice, as well as from humans who have recovered from COVID-19, in an effort to build a preventive cocktail treatment against the deadly respiratory disease.
To rapidly isolate an appropriate set of initial antibody candidates for COVID-19, the company's research and development team used VelocImmune mice, which have been genetically engineered to have a human immune system. Previously, Regeneron used this same technique to develop an experimental treatment for Ebola, which is currently under review with the Food and Drug Administration.
The big deal is that a safe and effective COVID-19 therapy would have mega-blockbuster sales potential. This ailment has now fanned out across the globe and killed over 7,500 people. So Regeneron's double-digit rally today seems to be justified, at least on the surface.
Regeneron hopes to begin human trials as soon as this summer. While a summer start is unquestionably a rapid development timeline for a complex biologic therapy, the bad news is that Gilead Sciences (NASDAQ:GILD) will probably have already released its remdesivir data by then.
That's not to say that remdesivir, Gilead's COVID-19 drug candidate, will make preventive treatments like Regeneron's unnecessary by any means. But its broad use could tamp down the current pandemic in a big way (assuming it's effective).
Put simply, Regeneron's COVID-19 therapy may not be the mega-blockbuster-in-the-making that the market seems to be forecasting, per today's action. Summer is a long way off, and a lot can happen by the time this biologic therapy is ready for widespread use in humans.